8 results about "Use insulin" patented technology

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor / PI3K / AKT / mTOR pathway, and / or use of diet that influences the subject's metabolic state.

The utility model provides a fixed application for an insulin pump, which relates to the technical field of medical instruments, and comprises an application, the application is used for fixing an infusion needle of the insulin pump, the infusion needle penetrates through the middle position in the application, one side of the infusion needle is connected with an infusion catheter, and the other side of the infusion needle is connected with an infusion tube. A fastening adhesive tape is arranged on the outer surface of the infusion catheter, and the fastening adhesive tape is used for fixing the infusion catheter; through the arrangement of the application and the fastening adhesive tape, the infusion needle head can be firmly fixed in the insulin pump, the fixing effect and the wearing comfort of the insulin pump are effectively improved, adverse effects of skin are reduced, and a better guarantee is provided for a patient to use the insulin pump.

This invention belongs to the field of fungal polysaccharide application technology, specifically relating to a method for preparing and applying polysaccharide from *Boletus globosum*. Crude polysaccharide was extracted from the fruiting body of *Boletus globosum* using hot water extraction, and purified using DEAE-52 cellulose column chromatography. Subsequently, by establishing an alcohol-induced liver injury model, it was found that NOP-1 significantly reduced ALT and AST levels, while simultaneously decreasing MDA content and increasing SOD activity and GSH levels, indicating that NOP-1 can inhibit lipid peroxidation, enhance the antioxidant defense capacity of hepatocytes, and maintain hepatocyte membrane integrity. A HepG2 cell IR model was constructed using a high-glucose, high-insulin combined induction method, determining the optimal dosage of NOP-1. ‑6 Treatment of HepG2 cells with mol / L insulin for 24 h successfully induced insulin resistance. Glucose consumption experiments in IR HepG2 cells demonstrated that NOP-1 significantly enhanced the glucose consumption capacity of insulin-resistant cells, exhibiting significant in vitro hypoglycemic activity.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present disclosure provides compositions including a polyacrylamide-based copolymer, one or more preservatives, and insulin or an analog thereof. Also provided are methods of using the insulin compositions, including methods of administering the compositions to a human subject in need thereof.

The invention discloses application of insulin in regulation and control of LC-PUFA (liquid chromatography-polyunsaturated fatty acid) biosynthesis of eriocheir sinensis, and belongs to the technical field of bioengineering. The invention provides an application of insulin in preparation of a preparation for regulating and controlling eriocheir sinensis LC-PUFA biosynthesis, insulin is taken as an active component, and the content of LC-PUFA is regulated and controlled in a targeted manner by improving the PIK3Ralpha gene expression of eriocheir sinensis. The invention further provides application of the combination of the insulin and the PI3K agonist 740Y-P in preparation of a preparation for regulating and controlling the LC-PUFA biosynthesis of the eriocheir sinensis. The invention also provides a preparation for regulating and controlling the LC-PUFA biosynthesis of the eriocheir sinensis, which comprises an effective amount of insulin as an active component and also comprises a PI3K agonist 740Y-P. Experiments prove that the insulin regulates and controls the LC-PUFA biosynthesis of the eriocheir sinensis in a targeted manner through a PIK3 signal channel, and a general strategy is provided for nutrition regulation and control of crustaceans.